The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours
- 105 Downloads
Gonadotroph tumours are the most abundant of the clinically silent pituitary tumours. There is a lack of reliable prognostic markers predicting their clinical course. Our aim was to determine the level of E-cadherin and N-cadherin in a cohort of clinically silent gonadotroph pituitary tumours, and compare them to the rate of reintervention.
Tumour tissue from primary surgery was retrospectively investigated and compared with clinical data. Immunohistochemical (N = 105) and real time-qPCR (N = 85) analyses for the levels of N-cadherin and the extra- and intracellular domains of E-cadherin were performed. The immunoreactive scores (IRS) and mRNA relative quantity were compared to the rate of reintervention.
The tumours presented a high IRS for N-cadherin (Median 12 (IQR 12-12)) and almost no immunoreactivity for the extracellular domain of E-cadherin (Median 0 (IQR 0-0)). The membranous staining for the intracellular domain of E-cadherin varied (Median 6 (IQR 4-6). Reduced membranous expression of the intracellular domain of E-cadherin was associated with nuclear presence of the same domain. Nuclear staining for the intracellular domain of E-cadherin was associated with a lower rate of reintervention (p = 0.01).
We found that silent gonadotroph tumours presented high IRS for N-cadherin and low IRS for the extracellular domain of E-cadherin. A substantial proportion of the tumours presented nuclear staining for the intracellular domain of E-cadherin, accompanied by a reduced membranous expression of the intracellular domain of E-cadherin. Absence of nuclear staining for the intracellular domain of E-cadherin served as an independent predictor of reintervention.
KeywordsPituitary adenomas PitNET EMT Cadherin Aggressiveness Gonadotroph pituitary tumours
The study was funded by the South-Eastern Norway Regional Health Authority Award (recipient KABØ), grant number 2016 026.
Compliance with ethical standards
Conflict of interest
Jens Bollerslev is a member of the Endocrine advisory board. The remaining authors declare that they have no conflict of interest.
The study was retrospective and did not include interventions involving human participants. The study was approved by the regional ethics committee and hospital authority.
Informed consent was obtained from all living patients included in the study.
- 1.S.L. Asa, O. Casar-Borota, P. Chanson, E. Delgrange, P. Earls, S. Ezzat, A. Grossman, H. Ikeda, N. Inoshita, N. Karavitaki, M. Korbonits, E.R. Laws Jr., M.B. Lopes, N. Maartens, I.E. McCutcheon, O. Mete, H. Nishioka, G. Raverot, F. Roncaroli, W. Saeger, L.V. Syro, A. Vasiljevic, C. Villa, A. Wierinckx, J. Trouillas, From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr. Relat. Cancer 24(4), C5–c8 (2017). https://doi.org/10.1530/erc-17-0004 CrossRefPubMedGoogle Scholar
- 4.A. Tjornstrand, K. Gunnarsson, M. Evert, E. Holmberg, O. Ragnarsson, T. Rosen, H. Filipsson Nystrom, The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur. J. Endocrinol. / Eur. Fed. Endocr. Soc. 171(4), 519–526 (2014). https://doi.org/10.1530/eje-14-0144 CrossRefGoogle Scholar
- 5.T.T. Agustsson, T. Baldvinsdottir, J.G. Jonasson, E. Olafsdottir, V. Steinthorsdottir, G. Sigurdsson, A.V. Thorsson, P.V. Carroll, M. Korbonits, R. Benediktsson, The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur. J. Endocrinol. / Eur. Fed. Endocr. Soc. 173(5), 655–664 (2015). https://doi.org/10.1530/eje-15-0189 CrossRefGoogle Scholar
- 6.E. Ferrante, M. Ferraroni, T. Castrignano, L. Menicatti, M. Anagni, G. Reimondo, P. Del Monte, D. Bernasconi, P. Loli, M. Faustini-Fustini, G. Borretta, M. Terzolo, M. Losa, A. Morabito, A. Spada, P. Beck-Peccoz, A.G. Lania, Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur. J. Endocrinol. / Eur. Fed. Endocr. Soc. 155(6), 823–829 (2006). https://doi.org/10.1530/eje.1.02298 CrossRefGoogle Scholar
- 9.S.L. Asa, A.M. Bamberger, B. Cao, M. Wong, K.L. Parker, S. Ezzat, The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J. Clin. Endocrinol. Metab. 81(6), 2165–2170 (1996). https://doi.org/10.1210/jcem.81.6.8964846 CrossRefPubMedGoogle Scholar
- 15.S. Yamada, K. Ohyama, M. Taguchi, A. Takeshita, K. Morita, K. Takano, T. Sano, A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61, 580–584 (2007). https://doi.org/10.1227/01.neu.0000290906.53685.79. discussion 584-585CrossRefPubMedGoogle Scholar
- 16.W. Zhou, Y. Song, H. Xu, K. Zhou, W. Zhang, J. Chen, M. Qin, H. Yi, J.A. Gustafsson, H. Yang, X. Fan, In nonfunctional pituitary adenomas, estrogen receptors and slug contribute to development of invasiveness. J. Clin. Endocrinol. Metab. 96(8), E1237–E1245 (2011). https://doi.org/10.1210/jc.2010-3040 CrossRefPubMedGoogle Scholar
- 17.M.S. Elston, A.J. Gill, J.V. Conaglen, A. Clarkson, R.J. Cook, N.S. Little, B.G. Robinson, R.J. Clifton-Bligh, K.L. McDonald, Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J. Clin. Endocrinol. Metab. 94(4), 1436–1442 (2009). https://doi.org/10.1210/jc.2008-2075 CrossRefPubMedGoogle Scholar
- 18.J. Torhorst, C. Bucher, J. Kononen, P. Haas, M. Zuber, O.R. Kochli, F. Mross, H. Dieterich, H. Moch, M. Mihatsch, O.P. Kallioniemi, G. Sauter, Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159(6), 2249–2256 (2001). https://doi.org/10.1016/s0002-9440(10)63075-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.O. Casar-Borota, A. Heck, S. Schulz, J.M. Nesland, J. Ramm-Pettersen, T. Lekva, I. Alafuzoff, J. Bollerslev, Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J. Clin. Endocrinol. Metab. 98(11), E1730–E1739 (2013). https://doi.org/10.1210/jc.2013-2145 CrossRefPubMedGoogle Scholar
- 22.W. Remmele, H.E. Stegner, [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Der Pathol. 8(3), 138–140 (1987)Google Scholar
- 23.M. Lee, A. Lupp, N. Mendoza, N. Martin, R. Beschorner, J. Honegger, J. Schlegel, T. Shively, E. Pulz, S. Schulz, F. Roncaroli, N.S. Pellegata, SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr. Relat. Cancer 22(1), 111–119 (2015). https://doi.org/10.1530/erc-14-0472 CrossRefPubMedGoogle Scholar
- 24.K.A. Oystese, O. Casar-Borota, K.R. Normann, M. Zucknick, J.P. Berg, J. Bollerslev, Estrogen receptor alpha, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA. J. Clin. Endocrinol. Metab. 102(9), 3581–3590 (2017). https://doi.org/10.1210/jc.2017-00792 CrossRefPubMedGoogle Scholar
- 25.K.R. Normann, K.A. Oystese, J.P. Berg, T. Lekva, J. Berg-Johnsen, J. Bollerslev, N.C. Olarescu, Selection and validation of reliable reference genes for RT-qPCR analysis in a large cohort of pituitary adenomas. Mol. Cell. Endocrinol. 437, 183–189 (2016). https://doi.org/10.1016/j.mce.2016.08.030 CrossRefPubMedGoogle Scholar
- 26.N. Chauvet, N. Romano, A.C. Meunier, E. Galibert, P. Fontanaud, M.N. Mathieu, G. Osterstock, P. Osterstock, E. Baccino, V. Rigau, H. Loiseau, S. Bouillot-Eimer, A. Barlier, P. Mollard, N. Coutry, Combining cadherin expression with molecular markers discriminates invasiveness in growth hormone and prolactin pituitary adenomas. J. Neuroendocrinol. 28(2), 12352 (2016). https://doi.org/10.1111/jne.12352 CrossRefPubMedGoogle Scholar
- 34.S.L. Fougner, T. Lekva, O.C. Borota, J.K. Hald, J. Bollerslev, J.P. Berg, The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metab. 95(5), 2334–2342 (2010). https://doi.org/10.1210/jc.2009-2197 CrossRefPubMedGoogle Scholar
- 35.J.A. Evang, J.P. Berg, O. Casar-Borota, T. Lekva, M.K. Kringen, J. Ramm-Pettersen, J. Bollerslev, Reduced levels of E-cadherin correlate with progression of corticotroph pituitary tumours. Clin. Endocrinol. 75(6), 811–818 (2011). https://doi.org/10.1111/j.1365-2265.2011.04109.x CrossRefGoogle Scholar
- 36.K. Ito, I. Okamoto, N. Araki, Y. Kawano, M. Nakao, S. Fujiyama, K. Tomita, T. Mimori, H. Saya, Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts. Oncogene 18(50), 7080–7090 (1999). https://doi.org/10.1038/sj.onc.1203191 CrossRefPubMedGoogle Scholar
- 37.S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, J. Bollerslev, Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76(1), 96–102 (2012). https://doi.org/10.1111/j.1365-2265.2011.04163.x CrossRefGoogle Scholar
- 38.P. Bouris, S.S. Skandalis, Z. Piperigkou, N. Afratis, K. Karamanou, A.J. Aletras, A. Moustakas, A.D. Theocharis, N.K. Karamanos, Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix biology: journal of the International Society for. Matrix Biol. 43, 42–60 (2015). https://doi.org/10.1016/j.matbio.2015.02.008 CrossRefPubMedGoogle Scholar
- 39.S.H. Park, L.W. Cheung, A.S. Wong, P.C. Leung, Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol. Endocrinol. 22(9), 2085–2098 (2008). https://doi.org/10.1210/me.2007-0512 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.J.H. Kim, J.H. Lee, J.H. Lee, A.R. Hong, Y.J. Kim, Y.H. Kim, Endoscopic transsphenoidal surgery outcomes in 331 nonfunctioning pituitary adenoma cases after a single surgeon learning curve. World Neurosurg. 109, e409–e416 (2017). https://doi.org/10.1016/j.wneu.2017.09.194 CrossRefPubMedGoogle Scholar
- 42.L.J. Lewis-Tuffin, F. Rodriguez, C. Giannini, B. Scheithauer, B.M. Necela, J.N. Sarkaria, P.Z. Anastasiadis, Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS. One. 5, e13665 (2010). https://doi.org/10.1371/journal.pone.0013665 CrossRefPubMedPubMedCentralGoogle Scholar